A Phase I Study of AB680 in Combination with AB122 Immunotherapy, Nab-Paclitaxel, and Gemcitabine in People with Advanced Pancreatic Cancer


Full Title

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies


The purpose of this study is to assess the safety of the investigational drugs AB680 and AB122 in combination with chemotherapy in people with advanced pancreatic cancer. By blocking a protein on cancer cells called CD73, AB680 may increase the immune system’s ability to find and kill pancreatic cancer cells. AB122 is also designed to harness the power of the immune system against cancer cells, by blocking a protein called PD1 and taking the brakes off the immune response.

Researchers in this study are seeking to find the highest dose of AB680 that can be given safely in combination with AB122, nab-paclitaxel, and gemcitabine. Nab-paclitaxel and gemcitabine are chemotherapy drugs routinely used in pancreatic cancer treatment. Combining the study drugs with chemotherapy may make the study drugs more effective against cancer. All medications used in this study are given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic pancreatic cancer that hasn’t been treated or has spread despite treatment that was completed more than 6 months before the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Eileen O’Reilly at 646-888-4182.




Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID